Assessing endoscopic remission in small bowel Crohn's disease:Are markers enough?  

作　　者：Iyad A Issa Taly Issa 

机构地区：[1]Department of Gastroenterology and Hepatology,Harley Street Medical Center,Abu Dhabi 41475,United Arab Emirates [2]Medical School,University of Nicosia,Nicosia 24005,Lefkosía,Cyprus

出　　处：《World Journal of Gastrointestinal Endoscopy》2025年第4期67-73,共7页世界胃肠内镜杂志(英文)

摘　　要：Mucosal healing in Crohn’s disease(CD)has been established as a crucial target of treatment,leading to long term remission and decrease in complication rates.Endoscopy still serves as the gold standard for assessment,particularly in the small bowel where balloon or capsule enteroscopy is frequently needed.However,these modalities are often unavailable,expensive,and invasive,posing risks to patients.Consequently,the identification of accessible and reliable biomarkers,especially in small intestinal CD,remains a challenge.The study by Ohno et al,published in this issue,further illuminates this field.It confirms the potential role of fecal biomarker leucine-richα2 glycoprotein(LRG)and validates findings from previous smaller trials.Comparing to other markers LRG showed a much higher predictive value for mucosal healing of the small bowel,making it a useful option for small intestinal CD follow up.In this editorial,we explore the optimal marker of inflammation or mucosal healing in CD,particularly in the small bowel.We provide an overview of available conventional biomarkers and introduce several novel biomarkers,including an update on emerging technologies and innovations.

关 键 词：Biomarker C-reactive protein Crohn’s disease Diagnosis Fecal calprotectin Inflammatory bowel disease Leucine-richα2 glycoprotein 

分 类 号：R574[医药卫生—消化系统]